Waleria HealthTech, an India-based supplier of botanical ingredients for women’s health, has spotlighted the publication of its randomized, double-blind, placebo-controlled study into the benefits of Aspurūs shatavari (Asparagus racemosus) in women with reduced sexual desire.
For eight weeks, 67 women aged 18-45 took either 300 mg per day of Aspurūs, a root extract standardized to 5% total shatavarins, or a matching placebo.
The primary outcome was change in total Female Sexual Function Index (FSFI) score. The authors reported that the shatavari group improved significantly more than placebo, with the largest gains seen in lubrication, orgasm and satisfaction.
Komal Baldwa, founder and CEO of Waleria, told NutraIngredients the improvement in vaginal lubrication was the most interesting finding of the study. Vaginal moisture, measured with the modified Schirmer test, rose by an average of 62.82% in the Aspurūs group, compared with a small decline in the placebo group.
The shatavari group also reported greater improvements than placebo on measures of anxiety and depression (24.81%), as well as the noted improvements in sleep disturbance (21.83%) and fatigue (60.05%).
Blood tests showed higher estradiol and lower cortisol and prolactin at day 56.
“Apart from the vaginal lubrication, there was also an improvement in sleep, fatigue, and stress,” said Baldwa. “So, that gives us more of a holistic view rather than just a focus on sexual health.”
There were no serious adverse events, and liver function markers and vital signs were stable, with two participants having mild, transient gastrointestinal symptoms.
The authors noted limitations including the modest sample size, single-site study and lack of partner data, and called for larger, multicenter studies.
Proposed mechanism
Shatavari is a plant native to India whose root is used in Ayurvedic medicine to aid in women’s reproductive health and as an aphrodisiac.
“Aspurūs balances cortisol levels and corrects hormonal imbalances while maintaining the HPA (Hypothalamic-Pituitary-Adrenal) and HPO (Hypothalamic-Pituitary-Ovarian) axis balance together,” explained Baldwa. “That’s how it helps to improve symptoms. Shatavari is also used in Ayurveda as an aphrodisiac because it helps balance the hormones.”
Baldwa further explained that when there is an imbalance between the HPO and HPA axis, the symptoms present differently depending on the hormonal stage of the individual.
She also drew attention to the complexity of the processes involved: when there is an increase in cortisol, stress increases and vaginal lubrication decreases, with the potential also for a reduction in testosterone leading to a reduction in libido. “The female body doesn’t work on a single mechanism – it’s a multi-part mechanism,” said Baldwa.
What sets Aspurūs apart
Waleria recently signed an exclusive US distribution deal with Maypro for Aspurūs, where the partners called attention to the seven naturally occurring shatavarins in the product.
Baldwa said Aspurūs differs from competing shatavari ingredients in two ways: “All the other suppliers take a one-size-fits-all approach. Aspurūs is personalized to specific life stages and we’re also the only one with all seven identified Shatavarins.”
Shatavarins, she explained, are bioactives that bind differently to different hormones, so a broad spectrum helps balance several hormones at once rather than raising a single one.
Asked whether Aspurūs could be applied to conditions such as PCOS, Baldwa said the company is taking a deeper dive into the mechanism. “We start from the hormones and then we come down,” she said. “So, we want to really understand more about the mechanism and how it works and then do a clinical study.”
She added that the company is also exploring use during the menstrual cycle, and has a study in progress.


